What Lacosam Treats: Main Uses and Therapeutic Benefits

Lacosam is a prescription antiepileptic medicine used to manage the abnormal electrical activity that causes symptoms related to heightened physiological activity in the brain. Its therapeutic role is relevant for managing the symptoms that result from abnormal electrical activity and may assist with easing the recurrence and impact of these disruptive episodes in adults and children aged four years and older.

This medication is commonly used to help with both partial-onset seizures (focal seizures) and primary generalized tonic-clonic seizures. It is generally utilized both as a standalone monotherapy and as an adjunctive therapy (used alongside other medicines) to support patients. The medication is applied to address symptoms of increased neurological activity associated with these events, thereby contributing to a reduction in the number of episodes and assisting with the associated involuntary muscle movements.

In complex clinical situations, Lacosam is considered relevant for patients with chronic epilepsy, particularly in conditions where symptoms may intensify temporarily and are refractory (difficult to treat) with initial therapies.

---

Quick Fact: Support for Uncontrolled Seizure Activity

Lacosam may assist with easing the overall symptom load during difficult episodes, which is relevant in cases of uncontrolled or recurrent seizure activity where maintaining stability is the primary clinical goal.

Lacosamide (Lacosam): Eligibility and Restrictions

Official regulatory documents define specific populations who are eligible, restricted, or strictly contraindicated for Lacosamide use. These rules are primarily based on age, cardiac status, and organ function.

Who Must Not Use Lacosamide (Contraindications)

Criteria	Status (Regulatory)
Hypersensitivity	Absolutely Contraindicated
Second- or Third-Degree AV Block	Absolutely Contraindicated (unless pacemaker is present)

---

Populations with Restricted Eligibility

Population Group	Restriction or Status
Severe Renal/Hepatic Impairment	Restricted: Lower maximum daily dose is mandated (e.g., 300 mg/day maximum)
Infants/Young Children	Not Established: Typically restricted to children ge 4 years of age for many indications
Pregnant/Breastfeeding Women	Not Recommended: Use is discouraged unless benefits clearly outweigh potential risks; substance is excreted in milk
PKU Patients	Ineligible for the oral solution due to aspartame content

---

General Eligibility

Lacosamide is generally approved for use in adults and children above the minimum established age threshold (e.g., 4 years) for its approved indications. Older adults may require cautious dose adjustments based on age-related declines in kidney function.

Interactions with other medicines and products

This section summarizes information regarding co-administration of Lacosam with other products, based on official government regulatory documents.

Pharmacokinetic Interaction Basis

Lacosam undergoes metabolism primarily mediated by the cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2C19. Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2C9 (e.g., fluconazole) may lead to an increase in the systemic exposure of Lacosam. No clinically relevant interaction has been observed with CYP2C19 inhibitors.

Pharmacodynamic Interaction Basis

Caution is warranted when Lacosam is co-administered with other medicinal products known to cause PR interval prolongation on the electrocardiogram. Examples of such drug classes include specific antiarrhythmics, Beta-Blockers, and Calcium Channel Blockers. This combination poses a risk of additive effects on cardiac conduction, particularly in patients with pre-existing cardiac conduction problems or severe cardiac disease.

Administration Requirements

Official regulatory information states that the presence of food does not affect the rate or extent of Lacosam's absorption; therefore, the product may be taken without regard to meals. There are no mandatory timing or separation requirements listed in relation to cation-containing antacids or other common binding agents. Specific electrocardiogram monitoring may be required when co-administering with PR-prolonging agents.

Lacosam, chemically lacosamide, modulates neuronal excitability primarily through its interaction with voltage-gated sodium channels (VGSCs) within the central nervous system. It functions as a positive allosteric modulator of the channel's slow inactivation process. The drug selectively enhances the rate and degree of slow inactivation, which is a state where the sodium channel pore is occluded for a prolonged duration, on a timescale of seconds to minutes.

This specific interaction with the slow inactivation phase stabilizes the neuronal membrane in a hyperpolarized state and limits the long-term availability of VGSCs for subsequent activation. The downstream cascade involves the inhibition of repetitive neuronal firing without significantly affecting the rapid, normal physiological function of the channels. Additionally, lacosamide binds to collapsin-response mediator protein 2 ( CRMP-2), a phosphoprotein involved in axonal guidance and neural plasticity, although the exact intracellular consequences of this interaction are still under investigation. The systemic physiological consequence is the stabilization of hyperexcitable neural membranes and reduction of abnormal electrical discharge frequency.

Lacosam (Lacosamide) is available in several forms and may be administered via two officially approved routes: Oral (tablet, oral solution, or extended-release capsule) and Intravenous (IV) Infusion. The IV route is typically used as a temporary alternative when the oral form is not feasible.

Official Dosing and Administration

Administration Parameter	Official Instruction Summary
Standard Adult Dosing	Treatment starts at a low dose, such as 50 mg twice daily (100 mg/day) for adjunctive therapy or 100 mg twice daily (200 mg/day) for monotherapy. Dosage increases are made gradually, usually at weekly intervals, by no more than 100 mg/day. The maximum recommended daily dose is typically 400 mg (200 mg twice daily) in the U.S., but may be up to 600 mg/day in Europe for monotherapy.
Loading Dose Option	Therapy can be initiated with a single 200 mg loading dose (oral or IV), followed 12 hours later by 100 mg twice daily.
Food and Timing	Oral forms can be taken with or without food. The medicine must be taken twice daily, approximately 12 hours apart.
Special Instructions	Tablets and extended-release capsules must be swallowed whole. The oral solution must be measured using a calibrated measuring device. IV infusions are typically administered over 30 to 60 minutes.
Missed Dose Rule	If a dose is missed, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and return to the regular schedule; do not take a double dose.

Dose Adjustments

Dosage adjustments are utilized for specific patient populations. For patients with severe renal impairment or end-stage renal disease, a dose reduction is necessary, and the maximum daily dosage is generally capped at 300 mg/day. Dosing for pediatric patients (typically 4 years and older) is weight-based (mg/kg/day). When discontinuing the medicine, a gradual withdrawal over at least one week is recommended.

Lacosam: Recent Clinical Evidence

Research has examined the combination of Drug A and Drug B and its potential role in research into Condition X. The studies focused on whether the combined approach could be associated with an observed change in key symptom measures compared to placebo or monotherapy.

---

Efficacy Studies

A key phase III clinical trial evaluated the two-drug regimen and observed a change in Patient Score Z over 12 weeks compared to placebo. This trial, involving 450 participants, was the primary source of data on the regimen’s short-term outcomes. The study examined the relationship between Drug A and study measures related to participant well-being, while Drug B was assessed based on how it was evaluated during the trial.

• Primary Outcome: The mean difference in Patient Score Z was observed between the groups after 12 weeks.
• Secondary Outcome: Evaluation of patients’ reported quality of life showed a numeric difference in the combination group over the placebo group.

A secondary analysis compared the combination with monotherapy with Drug A alone. The study protocols included starting treatment at the lowest dose to examine its potential impact on study results. Research also evaluated whether the two-drug regimen showed a difference in the time to relief than conventional treatments.

---

Safety and Side Effects Profile

Long-term use of this combination was evaluated for its safety profile. The trials monitored participants for a period of up to one year to capture delayed or cumulative effects.

Observed side effects included mild dizziness or upset stomach; these side effects were observed to conclude within a few days for some study participants. A minor observed risk of elevated heart rate was noted, and participants with heart conditions were a focus of safety observations in the trial.

Key Studies & References

1. Phase III Trial of Drug A and Drug B Combination in Condition X: Primary Efficacy and Safety Results
2. Comparative Analysis of Combined Drug A and Drug B vs. Monotherapy for Condition X

Common questions about Lacosam (FAQ)

---

Q: How is the effect of Lacosam different from other older anti-seizure medications?

Lacosam works in a unique way compared to many older medicines in its class. Official documents describe its action as selectively enhancing the slow inactivation of voltage-gated sodium channels. This specific mechanism is described as stabilizing nerve cells in the brain that are over-excited.

---

Q: How long does the dizziness side effect from Lacosam typically last when treatment is started?

Dizziness is classified as a very common side effect in official documents. It is most frequently observed during the initial period when the dosage is being gradually increased (titration). Official safety information indicates that this reaction may lessen or improve over time as the body adjusts to the medicine.

---

Q: Is blurred vision or double vision (diplopia) a very common side effect of Lacosam?

Double vision, known as diplopia, is listed in official documents as a very common adverse reaction. It is reported to occur in 10% or more of patients in clinical trials. Other vision changes are also reported.

---

Q: Why does Lacosam sometimes cause problems with coordination, walking, or balance?

Lack of muscle coordination, or ataxia, is classified as a common adverse reaction in official prescribing information. This effect is why some patients may experience problems with their balance or walking, particularly when starting the drug.

---

Q: Is it common to experience a tremor or shakiness in the hands or feet with Lacosam?

Tremor is listed as a common side effect in official documents, affecting 1% to less than 10% of patients in clinical trials. This effect is a known part of the neurological adverse reaction profile for this medicine.

---

Q: Are suicidal thoughts or behaviors recognized as a possible risk associated with Lacosam?

The official warning for antiepileptic drugs, including Lacosam, notes a potential increase in the risk of suicidal thoughts or behavior. Official warnings state that patients should be monitored for any unusual changes in mood or behavior while taking this medicine.

---

Q: Does Lacosam affect the effectiveness of hormonal birth control methods?

Based on official regulatory information and drug interaction studies, Lacosam is not known to affect the systemic exposure or effectiveness of hormonal contraceptives.

---

Q: Does Lacosam affect the results of routine blood tests for liver function or blood cell counts?

Official warnings highlight the potential for rare, serious systemic reactions that can affect organs like the liver. Monitoring for potential liver toxicity is mentioned in the prescribing information, which typically involves blood tests for liver function.

---

Q: What research evidence supports the use of Lacosam for treating focal seizures?

Lacosam is officially approved and supported by clinical study evidence for the treatment of partial-onset seizures. Partial-onset seizure is the official regulatory term for what are also commonly referred to as focal seizures.

---

Q: Are there specific instructions for managing withdrawal if a patient needs to taper off Lacosam?

Official prescribing information contains a recommendation for a gradual withdrawal over a minimum of one week. This instruction is to minimize the potential risk of increasing the frequency of seizures.

---

Q: Does Lacosam have a different use besides treating epilepsy?

According to official regulatory documents and indications, Lacosam is approved only for the treatment of specific types of seizures. These include partial-onset seizures in adults and certain pediatric patients.

---

Q: Can Lacosam cause memory impairment or difficulty concentrating?

Adverse effects reported from clinical experience include dizziness, somnolence (drowsiness), and a confusional state. These effects, as listed in the official label, can potentially affect concentration and thinking.

---

Q: What are the signs of a serious allergic reaction (DRESS) to Lacosam that I should know about?

DRESS is a rare but severe reaction that is mentioned in official safety documents. Signs may include a fever, a rash, and swelling of the face and lymph nodes. This reaction can also potentially lead to damage to internal organs such as the liver or kidney.

---

Q: Can Lacosam cause new or worsened confusion or agitation?

The official patient information lists potential behavioral changes, including feeling agitated or restless. Post-marketing reports also include cases of confusional state.

---

Q: How does consuming alcohol affect the safety or side effects of Lacosam?

Official interaction information indicates that consuming alcohol while taking Lacosam may increase certain nervous system side effects. These include feeling more dizzy, drowsy, confused, or having difficulty concentrating.

---

Q: Can common herbal supplements cause an interaction with Lacosam?

Official patient instructions state that patients should inform their healthcare provider about all medicines, vitamins, and herbal supplements they are taking. This information is requested due to the potential for interactions.

---

Q: How soon after starting Lacosam can a person expect to notice a difference in seizures?

Based on general drug information and clinical experience, it may take a few weeks or longer for a patient to experience the full, consistent therapeutic benefit of the medicine.

---

Q: What are the inactive ingredients in Lacosam tablets?

The official prescribing information for Lacosam lists all inactive ingredients, which can differ between the tablet, oral solution, and extended-release forms. The full list is available in the official prescribing information for each specific formulation.

---

Q: Are there any reported cases of Lacosam worsening seizure frequency or severity?

Official information notes that while the drug is intended to reduce seizures, a gradual withdrawal is recommended. This instruction is to minimize the potential risk of increased seizure frequency, which has been associated with sudden stopping of the drug.

---

Q: Can Lacosam cause aggressive behavior or mood swings, especially in children?

Official patient warnings list behavioral changes that require monitoring, including aggression, anger, violence, and new or worse irritability. These are recognized as possible effects, and the label specifies that patients of all ages should be monitored for these changes.

---

Q: What percentage of patients generally discontinue Lacosam due to adverse side effects?

Discontinuation rates due to adverse events are carefully monitored and vary across different clinical trials. Some long-term safety studies have reported low single-digit percentages of patients who stopped the medicine specifically due to side effects.

---

Q: Does Lacosam interact with other anti-seizure medications that also affect sodium channels?

Official assessments indicate that taking Lacosam alongside other antiepileptic drugs that block voltage-gated sodium channels may be associated with an increased risk of neurotoxicity. This can lead to increased side effects such as dizziness and double vision.

---

Q: What is the purpose of registering with the North American Antiepileptic Drug Pregnancy Registry?

The registry is an organized research effort whose primary objective is to estimate the risk of major congenital malformations. This is done by collecting data on infants whose mothers took antiepileptic drugs, including Lacosam, during the first trimester of pregnancy.

---

Q: What research has been done on the potential for Lacosam to cause long-term cognitive changes?

Clinical trials have included long-term safety evaluations for up to one year to monitor delayed or cumulative neurological and behavioral effects. Some studies have followed participants for up to one year to capture these types of potential long-term changes.

Storage and Disposal Requirements

Lacosamide tablets and oral solution must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, tightly closed, and stored away from excess heat and moisture. The oral solution must not be frozen.

As a controlled substance, Lacosamide must be kept out of the reach of children and secured in a safe place.

For stability, the oral solution has a shelf-life limit, requiring that any unused portion be discarded 6 months after the bottle is first opened.

To dispose of unused or expired Lacosamide, consult a healthcare professional or pharmacist. Any unused portion of the intravenous solution is intended for single use and must be discarded.